AI Article Synopsis
- Multigenic tests are crucial for selecting adjuvant therapy in early breast cancer patients with estrogen-positive and HER2-negative subtypes.
- The workflow associated with these tests can create a significant, often unrecognized workload for pathology labs, potentially delaying the start of treatment.
- The proposal for a "reflex testing" model suggests that pathologists should conduct multigene testing based on predefined criteria, aiming to streamline the process and enhance timely therapeutic interventions.
Article Abstract
Multigenic tests represent an essential tool for the selection of adjuvant therapy in estrogen-positive/HER2-negative (ER + /HER2-) early breast cancer (BC). The workflow of these tests, either if they are externalized or carried out in-house, generates a workload for the pathology laboratories, that is often underestimated and may affect timely therapy initiation. Here, we describe the evolving role of pathology laboratories in using multigenic tests and, more in general, in providing adequate tissue for molecular analyses. Moreover, we propose a “reflex testing” model, in which pathologists, based on pre-specified and shared criteria, are expected to action multigene testing independently of multidisciplinary team discussion in ER + /HER2- BC patients, in order to optimize turnaround time and proper therapy intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876915 | PMC |
| http://dx.doi.org/10.1038/s41523-023-00506-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!